Symbols

RNAM

Avidity Biosciences·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About RNAM

Avidity Biosciences, Inc.

A clinical stage biopharmaceutical company specializing in antibody oligonucleotide coupling(AOC)technology and focusing on rare diseases and muscle diseases

Industry

Biological Technology

Established Date

11/13/2012

Listing Date

06/12/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

511

Fiscal Year Ends

12-31

Website

www.aviditybiosciences.com

Security Type

Common stock

Office address

3020 Callan Road, San Diego, CA 92121

Business

Introduction

Avidity Biosciences, Inc., was incorporated on November 13, 2012 under the laws of the State of Delaware. The company is working on a new class of RNA therapies called antibody oligonucleotide conjugates (AOCs). Its proprietary AOC platform combines the specificity of monoclonal antibodies with the precision of RNA therapies to target previously incurable diseases. Avidity's pipeline includes three clinical development programs: delpacibart zotadirsen for Duchenne muscular dystrophy, delpacibart etedesiran for type 1 myotonic dystrophy, and delpacibart braxlosiran for facioscapulobrachial muscular dystrophy. All of these investigational therapies have received orphan designation and fast track status from regulatory agencies. In November 2025, Avidity announced its del-zota managed access program in the United States, providing access to eligible patients through an authorized treatment regimen.

Company Financials

EPS

RNAM has released its 2025 Q3 earnings. EPS was reported at -1.27, versus the expected -1.14, missing expectations. The chart below visualizes how RNAM has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

RNAM has released its 2025 Q4 earnings report, with revenue of 860.00K, reflecting a YoY change of -71.07%, and net profit of -237.10M, showing a YoY change of -131.87%. The Sankey diagram below clearly presents RNAM's revenue sources and cost distribution.